A bioinorganic perspectives on matrix metalloproteinase inhibition

Current Topics in Medicinal Chemistry

Volumn 4, Issue 15, 2004, Pages 1551-1573

  Puerta, David T ^a   Cohen, Seth M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug design; Matrix metalloproteinases; Metal chelation; Model compounds; Zinc

Indexed keywords

3 [4 [3 (CYANOMETHYL)PHENYL]PHENOXY]PROPANOHYDROXAMIC ACID; ALCOHOL DERIVATIVE; BARBITURIC ACID; BATIMASTAT; CARBOXYLIC ACID DERIVATIVE; COLLAGENASE; DOXYCYCLINE HYCLATE; FUTOENONE; GELATINASE; HERBACEOUS AGENT; HYDROXAMIC ACID DERIVATIVE; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE INHIBITOR; N (2 HYDROXAMATEMETHYLENE 4 METHYLPENTOYL)PHENYLALANYL)METHYLAMINE; NEUTROPHIL COLLAGENASE; PHOSPHONIC ACID DERIVATIVE; PNU 142372; PRINOMASTAT; PYRROLE DERIVATIVE; STROMELYSIN; TETRACYCLINE; THIOAMIDE; THIOKETONE; THIOL; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WAY 170523; ZINC ION; PROTEINASE INHIBITOR; ZINC DERIVATIVE;

ANALYTIC METHOD; ARTHRITIS; BONE PAIN; CANCER; CHEMICAL BINDING; COMPLEX FORMATION; DISEASE ASSOCIATION; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; HEART DISEASE; HUMAN; INORGANIC CHEMISTRY; MATHEMATICAL COMPUTING; MOLECULAR MODEL; MUSCULOSKELETAL DISEASE; MYALGIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PERIODONTAL DISEASE; PROTEIN FUNCTION; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; BINDING SITE; CHEMISTRY; CONFORMATION; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM;

ANIMALS; BINDING SITES; HUMANS; MATRIX METALLOPROTEINASES; MOLECULAR CONFORMATION; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; ZINC COMPOUNDS;

EID: 10844233846     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043387368     Document Type: Review

References (106)

1. Massova, I.; Kotra, L. P.; Fridman, R.; Mobashery, S. Matrix Metalloproteinases: Structures, Evolution, and Diversification. FASEB J 1998, 12, 1075-1095.
2. Matrisian, L. M. Metalloproteinases and Their Inhibitors in Matrix Remodeling. Trends Gen. 1990, 6, 121-125.
3. Shapiro, S. D. Matrix Metalloproteinase Degradation of Extracellular Matrix: Biological Consequences. Curr. Opin. Cell Biol. 1998, 10, 602-608.
4. Nagase, H.; Woessner, J. F., Jr. Matrix Metalloproteinases. J. Biol. Chem. 1999, 274, 21491-21494.
5. Gross, J.; Lapiere, C. M. Collagenolytic Activity in Amphibian Tissues: A Tissue Culture Assay. Proc. Natl. Acad. Sci. 1962, 48, 1014-1022.
6. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors. Chem. Rev. 1999, 99, 2735-2776.
7. Woessner, J. F.; Nagase, H. Matrix Metalloproteinases and TIMPs; Oxford Univ. Press: New York, 2000; Vol. 1.
8. Sternlicht, M. D.; Werb, Z. How Matrix Metalloproteinases Regulate Cell Behavior. Annu. Rev. Cell Dev. Biol. 2001, 17, 463-516.
9. Babine, R. E.; Bender, S. L. Molecular Recognition of Protein-Ligand Complexes: Applications to Drug Design. Chem. Rev. 1997, 97, 1359-1472.
10. Skiles, J. W.; Gonnella, N. C.; Jeng, A. Y. The Design, Structure, and Therapeutic Application of Matrix Metalloproteinase Inhibitors. Curr. Med. Chem. 2001, 8, 425-474.
11. Brinckerhoff C. E.; Matrisian, L. M. Matrix Metalloproteinases: A Tail of a Frog that Became a Prince. Nat. Rev. Mol. Cell Biol. 2002, 3, 207-214.
12. Rohde, L. E.; Ducharme, A.; Arroyo, L. H.; Aikawa, M.; Sukhova, G. H.; Lopez-Anaya, A.; McClure, K. F.; Mitchell, P. G.; Libby, P.; Lee, R. T. Matrix Metalloproteinase Inhibition Attenuates Early Left Ventricular Enlargement After Experimental Myocardial Infarction in Mice. Circulation 1999, 99, 3063-3070.
13. Stetler-Stevenson, W. G. Matrix Metalloproteinases in Angiogenesis: A Moving Target for Theraputic Intervention. J. Clin. Invest. 1999, 103, 1237-1241.
14. Vu, T. H.; Shipley, J. M.; Bergers, G.; Berger, J. E.; Helms, J. A.; Hanahan, D.; Shapiro, S. D.; Senior, R. M.; Werb, Z. MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes. Cell 1998, 93, 411-422.
15. Chambers, A. F.; Matrisian, L. M. Changing Views of the Role of Matrix Metalloproteinases in Metastasis. J. Natl. Cancer Inst. 1997, 89, 1260-1270.
16. Brown, D. L.; Hibbs, M. S.; Kearney, M.; Loushin, C.; Isner, J. M. Identification of 92-kD Gelatinase in Human Coronary Atherosclerotic Lesions: Association of Active Enzyme Synthesis with Unstable Angina. Circulation 1995, 91, 2125-2131.
17. Billinghurst, R. C.; Dahlberg, L.; Ionescu, M.; Reiner, A.; Bourne, R.; Rorabeck, C.; Mitchell, P.; Hambor, J.; Diekmann, O.; Tschesche, H.; Chen, J.; Wart, H. V.; Poole, A. R. Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage. J. Clin. Invest. 1997, 99, 1534-1545.
18. Mitchell, P. G.; Magna, H. A.; Reeves, L. M.; Lopresti-Morrow, L.L.; Yocum, S. A.; Rosner, P. J.; Geoghegan, K. F.; Hambor, J. E. Cloning, Expression, and Type II Collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage. J. Clin. Invest. 1996, 97, 761-768.
19. Kim, H. E.; Dalal, S, S.; Young, E.; Legato, M. J.; Weisfeldt, M. L.; D'Armiento, J. Disruption of the Myocardial Extracellular Matrix Leads to Cardiac Dysfunction. J. Clin. Invest. 2000, 106, 857-866.
20. Wilson, C. L.; Heppner, K. J.; Labosky, P. A.; Hogan, B. L. M.; Matrisian, L. M. Intestinal Tumorigenesis is Suppressed in Mice Lacking the Metalloproteinase Matrilysin. Proc. Natl. Acad. Sci. 1997, 94, 1402-1407.
21. Itoh, T.; Tanioka, M.; Yoshida, H.; Yoshioka, T.; Nishimoto, H.; Itohara, S. Reduced Angiogenesis and Tumor Progression in Gelatinase A-Deficient Mice. Cancer Res. 1998, 58, 1048-1051.
22. Bertini, I.; Calderone, V.; Fragai, M.; Luchinat, C.; Mangani, S.; Terni, B. X-ray Structures of Binary and Ternary Enzyme-Product-Inhibitor Complexes of Matrix Metalloproteinases. Angew. Chem. Int. Ed. 2003, 42, 2673-2676.
23. Kojima, S.; Itoh, Y.; Matsumoto, S,; Masuho, Y.; Seiki, M. Membrane-type 6 Matrix Metalloproteinase (MT6-MMP, MMP-25) is the Second Glycosyl-Phosphatidyl Inositol (GPI)-Anchored MMP. FEBS Lett. 2000, 480, 142-146.
24. Kang, T.; Yi, J.; Guo, A.; Wang, X.; Overall, C. M.; Jiang, W.; Elde, R.; Borregaard, N.; Pei, D. Subcellular Distribution and Cytokine- and Chemokine-regulated Secretion of Leukolysin/MT6-MMP/MMP-25 in Neutrophils. J. Biol. Chem. 2001, 276, 21960-21968.
25. Terp, G. E.; Cruciani, G.; Christensen, I. T.; Jørgensen, F. S. Structural Differences of Matrix Metalloproteinases with Potential Implications for Inhibitor Selectivity Examined by the GRID/CPCA Approach. J. Med. Chem. 2002, 45, 2675-2684.
26. Overall, C. M.; López-Otín, C. Strategies for MMP Inhibition in Cancer: Innovations for the Post-trial Era. Nat. Rev. Cancer 2002, 2, 657-672.
27. Gomis-Rüth, F.-X.; Maskos, K.; Betz, M.; Bergner, A.; Huber, R.; Suzuki, K.; Yoshida, N.; Nagase, H.; Brew, K.; Bourenkov, G. P.; Bartunik, H.; Bode, W. Mechanism of Inhibition of the Human Matrix Metalloproteinase Stromelysin-1 by TIMP-1. Nature 1997, 389, 77-81.
28. Bode, W.; Fernandez-Catalan, C.; Grams, F.; Gomis-Rüth, F.-X.; Nagase, H.; Tschesche, H.; Maskos, K. Insights into MMP-TIMP Interactions. Ann. Proc. N. Y. Acad. Sci. 1999, 878, 73-91.
29. Bode, W.; Fernandez-Catalan, C.; Tschesche, H.; Grams, F.; Nagase, H.; Maskos, K. Structural Properties of Matrix Metalloproteinases. Cell. Mol. Life. Sci. 1999, 55, 639-652.
30. Fernandez-Catalan, C.; Bode, W.; Huber, R.; Turk, D.; Calvete, J. J.; Lichte, A.; Tschesche, H.; Maskos, K. Crystal Structure of the Complex Formed by the Membrane Type 1-Matrix Metalloproteinase with the Tissue Inhibitor of Metalloproteinases-2, the Soluble Progelatinase A Receptor. EMBO J. 1998, 17, 5238-5248.
31. Martin, D. C.; Sanchez-Sweatman, O. H.; Ho, A. T.-V.; Inderdeo, D. S.; Tsao, M.-S.; Khokha, R. Transgenic TIMP-1 Inhibits Simian Virus 40 T Antigen-Induced Hepatocarcinogenesis by Impairment of Hepatocellular Proliferation and Tumor Angiogenesis. Lab. Invest. 1999, 79, 225-234.
32. Krüger, A.; Fata, J. E.; Khokha, R. Altered Tumor Growth and Metastasis of a T-Cell Lymphoma in TIMP-1 Transgenic Mice. Blood 1997, 90, 1993-2000.
33. Cal, S.; Obaya, A. J.; Llamazares, M.; Garabaya, C.; Quesada, V.; López-Otín, C. Cloning, Expression Analysis, and Structural Characterization of Seven Novel Human ADAMTSs, a Family of Metalloproteinases with Disintegrin and Thrombospondin-1 Domains. Gene 2002, 283, 49-62.
34. Andrews, H. J.; Plumpton, T. A.; Harper, G. P.; Cawston, T. E. A Synthetic Peptide Metalloprotease Inhibitor, but not TIMP, Prevents the Breakdown of Proteoglycan Within Articular Cartilage in vitro. Agents Actions 1992, 37, 147-154.
35. Lovejoy, B.; Welch, A. R.; Carr, S.; Luong, C.; Broka, C.; Hendricks, R. T.; Campbell, J. A.; Walker, K. A. M.; Martin, R.; Van Wart, H.; Browner, M. F. Crystal Structures of MMP-1 and - 13 Reveal the Structural Basis for Selectivity of Collagenase Inhibitors. Nat. Struct. Biol. 1999, 6, 217-221.
36. Hajduk, P. J.; Sheppard, G.; Nettesheim, D. G.; Olejniczak, E. T.; Shuker, S. B.; Meadows, R. P.; Steinman, D. H.; Carrera. Jr., G. M.; Marcotte, P. A.; Severin, J.; Walter, K.; Smith, H.; Gubbins, E.; Simmer, R.; Holzman, T. F.; Morgan, D. W.; Davidsen, S. K.; Summers, J. B.; Fesik, S. W. Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR. J. Am. Chem. Soc. 1997, 119, 5818-5827.
37. Olejniczak, E. T.; Hajduk, P. J.; Marcotte, P. A.; Nettesheim, D. G.; Meadows, R. P.; Edalji, R.; Holzman, T. F.; Fesik, S. W. Stromelysin Inhibitors Designed from Weakly Bound Fragments: Effects of Linking and Cooperativity. J. Am. Chem. Soc. 1997, 119 5828-5832.
38. Chen, J. M.; Nelson, F. C.; Levin, J. I.; Mobilio, D.; Moy, F. J.; Nilakantan, R.; Zask, A.; Powers, R. Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design. J. Am. Chem. Soc. 2000, 122, 9648-9654.
39. Pikul, S.; Dunham, K. M.; Almstead, N. G.; De, B.; Natchus, M. G.; Taiwo, Y. O.; Williams, L. E.; Hynd, B. A.; Hsieh, L. C.; Janusz, M. J.; Go, F.; Mieling, G. E. Heterocycle-Based MMP Inhibitors with P2′ Substiments. Bioorg. Med. Chem. Lett. 2001, 11, 1009-1013.
40. Hirayama, R.; Yamamoto, M.; Tsukida, T.; Matsuo, K.; Obata, Y.; Sakamoto, F.; Ikeda, S. Synthesis and Biological Evaluation of Orally Active Matrix Metalloproteinase Inhibitors. Bioorg. Med. Chem. 1997, 5, 765-778.
41. Fray, M. J.; Burslem, M. F.; Dickinson, R. P. Selectivity of Inhibition of Matrix Metalloproteases MMP-3 and MMP-2 by Succinyl Hydroxamates and their Carboxylic Acid Analogues is Dependent on P3′ Group Chirality. Bioorg. Med. Chem. Lett. 2001, 11, 567-570.
42. Chen, E. I.; Li, W.; Godzik, A.; Howard, E. W.; Smith, J. W. A Residue in the S2 Subsite Controls Substrate Selectivity of Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9. J. Biol. Chem. 2003, 278, 17158-17163.
43. Finzel, B. C.; Baldwin, E. T.; Bryant Jr., G. L.; Hess, G. F.; Wilks, J. W.; Trepod, C. M.; Mott, J. E.; Marshall, V. P.; Petzold, G. L.; Poorman, R. A.; O'Sullivan, T. J.; Schostarez, H. J.; Mitchell, M. A. Structural Characterizations of Nonpeptide Thiadiazole Inhibitors of Matrix Metalloproteinases Reveal the Basis for Stromelysin Selectivity. Protein Sci. 1998, 7, 2118-2126.
44. Yeh, L.-A.; Chen, J.; Baculi, F.; Gingrich, D. E.; Shen, T. Y. Inhibition of Metalloproteinase by Futoenone Derivatives. Bioorg. Med. Chem. Lett. 1995, 5, 1637-1642.
45. Reiter, L. A.; Mitchell, P. G.; Martinelli, G. J.; Lopresti-Morrow, L. L.; Yocum, S. A.; Eskra, J. D. Phosphinic Acid-Based MMP-13 Inhibitors That Spare MMP-1 and MMP-3, Bioorg. Med. Chem. Lett. 2003, 13, 2331-2336.
46. Addison, A. W.; Rao, T. N.; Reedijk, J.; van Rijn, J.; Verschoor, G. C. Synthesis, Structure, and Spectroscopic Properties of Copper(II) Compounds Containing Nitrogen-Sulphur Donor Ligands; the Crystal and Molecular Structure of Aqua [1,7-bis(N-methylbenzimidazol-2′-yl)-2,6-dithiaheptane]copper(II) Perchlorate. J. Chem. Soc. Dalton Trans. 1984, 1349-1356.
47. Almstead, N. G.; Bradley, R. S.; Pikul, S.; De, B.; Natchus, M. G.; Taiwo, Y. O.; Gu, F.; Williams, L. E.; Hynd, B. A.; Janusz, M. J.; Dunaway, C. M.; Mieling, G. E. Design, Synthesis, and Biological Evaluation of Potent Thiazine-and Thiazepine-Based Matrix Metalloproteinase Inhibitors. J. Med. Chem. 1999, 42, 4547-4562.
48. Bode, W.; Reinemer, P.; Huber, R.; Kleine, T.; Schnierer, S.; Tschesche, H. The X-ray Crystal Structure of the Catalytic Domain of Human Neutrophil Collagenase Inhibited by a Substrate Analogue Reveals the Essentials for Catalysis and Specificity. EMBO J. 1994, 13, 1263-1269.
49. Cheng, M.; De, B.; Almstead, N. G.; Pikul, S.; Dowty, M. E.; Dietsch, C. R.; Dunaway, C. M.; Gu, F.; Hsieh, L. C.; Janusz, M. J.; Taiwo, Y. O.; Natchus, M. G.; Hudlicky, T.; Mandel, M. Design, Synthesis, and Biological Evaluation of Matrix Metalloproteinase Inhibitors Derived from a Modified Proline Scaffold. J. Med. Chem. 1999, 42 5426-5436.
50. Natchus, M. G.; Bookland, R. G.; De, B.; Almstead, N. G.; Pikul, S.; Janusz, M. J.; Heitmeyer, S. A.; Hookfin, E. B.; Hsieh, L. C.; Dowty, M. E.; Dietsch, C. R.; Patel, V. S.; Garver, S. M.; Gu, F.; Pokross, M. E.; Mieling, G. E.; Baker, T. R.; Foltz, D. J.; Peng, S. X.; Bornes, D. M.; Strojnowski, M. J.; Taiwo, Y. O. Development of New Hydroxamate Matrix Metalloproteinase Inhibitors Derived from Functionalized 4-Aminoprolines. J. Med. Chem. 2000, 43, 4948-4963.
51. Chen, L.; Rydel, T. J.; Gu, F.; Dunaway, C. M.; Pikul, S.; McDow Dunham, K.; Barnett, B. L. Crystal Structure of the Stromelysin Catalytic Domain at 2.0 Å Resolution: Inhibitor-induced Conformational Changes. J. Mol. Biol. 1999, 293, 545-557.
52. Grams, F.; Reinemer, P.; Powers, J. C.; Kleine, T.; Pieper, M.; Tschesche, H.; Huber, R.; Bode, W. X-ray Structures of Human Neutrophil Collagenase Complexed with Peptide Hydroxamate and Peptide Thiol Inhibitors: Implications for Substrate Binding and Rational Drug Design. Eur. J. Biochem. 1995, 228, 830-841.
53. Betz, M.; Huxley, P.; Davies, S.-J.; Mushtaq, Y.; Pieper, M.; Tschesche, H.; Bode, W.; Gomis-Ruth, F.-X. 1,8-Å Crystal Structure of the Catalytic Domain of Human Neutrophil Collagenase (Matrix Metalloproteinase-8) Complexed with a Peptidomimetic Hydroxamate Primed-Side Inhibitor with a Distinct Selectivity Profile. Eur. J. Biochem. 1997, 247, 356-363.
54. Browner, M. F.; Smith, W. W.; Castelhano, A. L. Matrilysin-Inhibitor Complexes: Common Themes Among Metalloproteases. Biochemistry 1995, 34, 6602-6610.
55. Natchus, M. G.; Bookland, R. G.; Laufersweiler, M. J.; Pikul, S.; Almstead, N. G.; De, B.; Janusz, M. J.; Hsieh, L. C.; Gu, F.; Pokross, M. E.; Patel, V. S.; Garver, S. M.; Peng, S. X.; Branch, T. M.; King, S. L.; Baker, T. R.; Foltz, D. J.; Mieling, G. E. Development of New Carboxylic Acid-Based MMP Inhibitors Derived from Functionalized Propargylglycines. J. Med. Chem. 2001, 44, 1060-1071.
56. Esser, C. K.; Bugianesi, R. L.; Caldwell, C. G.; Chapman, K. T.; Durette, P. L.; Girotra, N. N.; Kopka, I. E.; Lanza, T. J.; Levorse, D. A.; MacCoss, M.; Owens, K. A.; Ponpipom, M. M.; Simeone, J. P.; Harrison, R. K.; Niedzwiecki, L.; Becker, J. W.; Marcy, A. I.; Axel, M. G.; Christen, A. J.; McDonnell, J.; Moore, V. L.; Olszewski, J. M.; Saphos, C.; Visco, D. M.; Shen, F.; Colletti, A.; Krieter, P. A.; Hagmann, W. K. Inhibition of Stromelysin-1 (MMP-3) by P1′-Biphenylylethyl Carboxyalkyl Dipeptides. J. Med. Chem. 1997, 40, 1026-1040.
57. Pavlovsky, A. G.; Williams, M. G.; Ye, Q.-Z.; Ortwine, D. F.; Purchase II, C. F.; White, A. D.; Dhanaraj, V.; Roth, B. D.; Johnson, L. L.; Hupe, D.; Humblet, C.; Blundell, T. L. X-Ray Structure of Human Stromelysin Catalytic Domain Complexed with Nonpeptide Inhibitors: Implications for Inhibitor Selectivity. Protein Sci. 1999, 8, 1455-1462.
58. Matter, H.; Schwab, W.; Barbier, D.; Billen, G.; Haase, B.; Neises, B.; Schudok, M.; Thorwart, W.; Schreuder, H.; Brachvogel, V.; Lönze, P.; Weithmann, K. U. Quantitative Structure-Activity Relationship of Human Neutrophil Collagenase (MMP-8) Inhibitors Using Comparative Molecular Field Analysis and X-ray Structure Analysis. J. Med. Chem. 1999, 42, 1908-1920.
59. Becker, J. W.; Marcy, A. I.; Rokosz, L. L.; Axel, M. G.; Burbaum, J. J.; Fitzgerald, P. M. D.; Cameron, P. M.; Esser, C. K.; Hagmann, W. K.; Hermes, J. D.; Springer, J. P. Stromelysin-1: Three-Dimensional Structure of the Inhibited Catalytic Domain and of the C-Truncated Proenzyme. Protein Sci. 1995, 4, 1966-1976.
60. Ph = Hydrotris(3-phenylpyrazol-1-yl)borate, acae = Pentane-2,4-dionate, and M = Zn, Co). Inorg. Chem. 1997, 36, 1552-1563.
61. Darensbourg, D. J.; Wildeson, J. R.; Yarbrough, J. C. Solid-State Structures of Zinc(II) Benzoate Complexes. Catalyst Precursors for the Coupling of Carbon Dioxide and Epoxides. Inorg. Chem. 2002, 41, 973-980.
62. O'Brien, P. M.; Ortwine, D. F.; Pavlovsky, A. G.; Picard, J. A.; Sliskovic, D. R.; Roth, B. D.; Dyer, R. D.; Johnson, L. L.; Man, C. F.; Hallak, H. Structure-Activity Relationships and Pharmacokinetic Analysis for a Series of Potent, Systemically Available Biphenylsulfonamide Matrix Metalloproteinase Inhibitors. J. Med. Chem. 2000, 43, 156-166.
63. Campbell, D. A.; Xiao, X.-Y.; Harris, D.; Ida, S.; Mortezaei, R.; Ngu, K.; Shi, L.; Tien, D.; Wang, Y.; Navre, M.; Patel, D. V.; Sharr, M. A.; DiJoseph, J. F.; Killar, L. M.; Leone, C. L.; Levin, J. I.; Skotnicki, J. S. Malonyl α-Mereaptoketones and α -Mercaptoalcohols, A New Class of Matrix Metalloproteinase Inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 1157-1162.
64. Freskos, J. N.; McDonald, J. J.; Mischke, B. V.; Mullins, P. B.; Shieb, H.-S.; Stegeman, R. A.; Stevens, A. M. Synthesis and Identification of Conformationally Constrained Selective MMP Inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 1757-1760.
65. Levin, J. I.; DiJoseph, J. F.; Killar, L. M.; Sharr, M. A.; Skotnicki, J. S.; Patel, D. V.; Xiao, X.-Y.; Shi, L.; Navre, M.; Campbell, D. A. The Asymmetric Synthesis and In Vitro Characterization of Succinyl Mercaptoalcohol and Mercaptoketone Inhibitors of Matrix Metalloproteinases. Bioorg. Med. Chem. Lett. 1998, 8, 1163-1168.
66. Baxter, A. D.; Bird, J.; Bhogal, R.; Massil, T.; Minton, K. J.; Montana, J.; Owen, D. A. A Novel Series of Matrix Metalloproteinase Inhibitors for the Treatment of Inflammatory Disorders. Bioorg. Med. Chem. Lett. 1997, 7, 897-902.
67. Hughes, I.; Harper, G. P.; Karran, E. H.; Markwell, R. E,; Miles-Williams, A. J. Synthesis of Thiophenol Derivatives as Inhibitors of Human Collagenase. Bioorg. Med. Chem. Lett. 1995, 5, 3039-3042.
68. Parkin, G. The Bioinorganic Chemistry of Zinc: Synthetic Analogues of Zinc Enzymes that Feature Tripodal Ligands. Chem. Comm. 2000, 1971-1985.
69. Morgunova, E.; Tuuttila, A.; Bergmann, U.; Isupov, M.; Lindqvist, Y.; Schneider, G.; Tryggvason, K. Structure of Human Pro-Matrix Metalloproteinase-2: Activation Mechanism Revealed. Science 1999, 284, 1667-1670.
70. Komiyama, T.; Aoyagi, T.; Takeuchi, T.; Umezawa, H. Inhibitory Effects of Phosphoramidon on Neutral Metallendopeptidases and its Application on Affinity Chromatography. Biochem. Biophys. Res. Comm. 1975, 65, 352-357.
71. Gavuzzo, E.; Pochetti, G.; Mazza, F.; Gallina, C.; Gorini, B.; D'Alessio, S.; Pieper, M.; Tschesche, H.; Tucker, P. A. Two Crystal Structures of Human Neutrophil Collagenase, One Complexed with a Primed- and the Other with an Unprimed-Side Inhibitor: Implications for Drug Design. J. Med. Chem. 2000, 43, 3377-3385.
72. Gall, A.-L.; Ruff, M.; Kannan, R.; Cuniasse, P.; Yiotakis, A.; Dive, V.; Rio, M.-C.; Basset, P.; Moras, D. Crystal Structure of the Stromelysin-3 (MMP-11) Catalytic Domain Complexed With a Phosphinic Inhibitor Mimicking the Transition-state. J. Mol. Biol. 2001, 307, 577-586.
73. Rowsell, S.; Hawtin, P.; Minshull, C. A.; Jepson, H.; Brockbank, S. M. V.; Barratt, D. G.; Slater, A. M.; McPheat, W. L.; Waterson, D.; Henney, A. M.; Pauptit R. A. Crystal Structure of Human MMP9 in Complex with a Reverse Hydroxamate Inhibitor. J. Mol. Biol. 2002, 319, 173-181.
74. Szardenings, A. K.; Antonenko, V.; Campbell, D. A.; DeFrancisco, N.; Ida, S.; Shi, L.; Sharkov, N.; Tien, D.; Wang, Y.; Navre, M. Identification of Highly Selective Inhibitors of Collagenase-1 from Combinatorial Libraries of Diketopiperazines. J. Med. Chem. 1999, 42, 1348-1357.
75. Stockman, B. J.; Waldon, D. J.; Gates, J. A.; Scahill, T. A.; Kloosterman, D. A.; Mizsak, S. A.; Jacobsen, E. J.; Belonga, K. L.; Mitchell, M. A.; Mao, B.; Petke, J. D.; Goodman, L.; Powers, E. A.; Ledbetter, S. R.; Kaytes, P. S.; Vogeli, G.; Marshall, V. P.; Petzold, G. L.; Poorman, R. A. Solution structures of stromelysin complexed to thiadiazole inhibitors. Protein Sci. 1998, 7, 2281-2286.
76. Dunten, P.; Kammlott, U.; Crowther, R.; Levin, W.; Foley, L. H.; Wang, P.; Palermo, R. X-ray Structure of a Novel Matrix Metalloproteinase Inhibitor Complexed to Stromelysin. Protein Sci. 2001, 10, 923-926.
77. Brandstetter, H.; Grams, F.; Glitz, D.; Lang, A.; Huber, R.; Bode, W.; Krell, H.-W.; Engh, R. A. The 1.8-Å Crystal Structure of a Matrix Metalloproteinase 8-Barbiturate Inhibitor Complex Reveals a Previously Unobserved Mechanism for Collagenase Substrate Recognition. J. Biol. Chem. 2001, 276, 17405-17412.
78. Foley, L. H.; Palermo, R.; Dunten, P.; Wang, P. Novel 5,5-Disubstitutedpyrimidine-2,4,6-Triones as Selective MMP Inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 969-972.
79. Golub, L. M.; Lee, H.-M.; Ryan, M. E.; Giannobile, W. V.; Payne, J.; Sorsa, T. Tetracyclines Inhibit Connective Tissue Breakdown By Multiple Non-Antimicrobial Mechanisms. Adv. Dent. Res. 1998, 12, 12-26.
80. Duivenvoorden, W. C. M.; Popovic, S. V.; Lhoták, S.; Seidlitz, E.; Hirte, H. W.; Tozer, R. G.; Singh, G. Doxycycline Decreases Tumor Burden in a Bone Metastasis Model of Human Breast Cancer. Cancer Res. 2002, 62, 1588-1591.
81. Sepper, R.; Konttinen, Y. T.; Ding, Y.; Takagi, M.; Sorsa, T. Human Neutrophil Collagenase (MMP-8), Identified in Bronchiectasis BAL Fluid, Correlates With Severity of Disease. Chest 1995, 107, 1641-1647.
82. Gilbertson-Beadling, S.; Powers, E. A.; Stamp-Cole, M.; Scott, P. S.; Wallace, T. L.; Copeland, J.; Petzold, G.; Mitchell, M.; Ledbetter, S.; Poorman, R. The Tetracycline Analogs Minocycline and Doxycycline Inhibit Angiogenesis in Vitro by a Non-Metalloproteinase-Dependent Mechanism. Cancer Chemother. Pharmacol 1995, 36, 418-424.
83. Schneider, S. In Tetracyclines in Biology, Chemistry and Medicine; Nelson, M., Hillen, W., Greenwald, R. A., Eds.; Birkhauser Verlag: Basel, 2001, pp 65-104.
84. Puerta, D. T.; Schames, J. R.; Henchman, R. H.; McCammon, J. A.; Cohen, S. M. From Model Complexes to Metalloprotein Inhibition: A Synergistic Approach to Structure-Based Drug Discovery. Angew. Chem. Int. Ed. 2003, 42, 3772-3774.
85. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix Metalloproteinase Inhibitors and Cancer: Trials and Tribulations. Science 2002, 295, 2387-2391
86. Hutchinson, J. W.; Tierney, G. M.; Parsons, S. L.; Davis, T. R. C. Dupuytren's Disease and Frozen Shoulder Induced by Treatment with a Matrix Metalloproteinase Inhibitor. J. Bone Joint Surg. [Br] 1998, 80-B, 907-908.
87. Krüger, A.; Soeltl, R.; Sopov, I.; Kopitz, C.; Arlt, M.; Magdolen,V.; Harbeck, N.; Gänsbacher, B.; Schmitt, M. Hydroxamate-Type Matrix Metalloproteinase Inhibitor Batimastat Promotes Liver Metastasis. Cancer Res. 2001, 61, 1272-1275.
88. Puerta, D. T.; Cohen, S. M. Elucidating Drug-Metalloprotein Interactions with Tris(pyrazolyl)borate Model Complexes. Inorg. Chem. 2002, 41, 5075-5082.
89. Hajduk, P. J.; Shuker, S. B.; Nettesheim, D. G.; Craig, R.; Augeri, D. J.; Betebenner, D.; Albert, D. H.; Guo, Y.; Meadows, R. P.; Xu, L.; Michaelides, M.; Davidsen, S. K.; Fesik, S. W. NMR-Based Modification of Matrix Metalloproteinase Inhibitors with Improved Bioavailability. J. Med. Chem. 2002, 45, 5628-5639.
90. Singh, J.; Conzentino, P.; Cundy, K.; Gainor, J. A.; Gilliam, C. L.; Gordon, T. D.; Johnson, J. A.; Morgan, B. A.; Schneider, E. D.; Wahl, R. C.; Whipple, D. A. Relationship Between Structure and Bioavailability in a Series of Hydroxamate Based Metalloproteinase Inhibitors. Bioorg. Med Chem. Lett. 1995, 5, 337-342.
91. Summers, J. B.; Gunn, B. P.; Mazdiyasni, H.; Goetze, A. M.; Young, P. R.; Bouska, J. B.; Dyer, R. D.; Brooks, D. W.; Carter, G. W. In Vitro Characterization of Hydroxamic Acid Inhibitors of 5-Lipoxygenase. J. Med. Chem. 1987, 30, 2121-2126.
92. Farkas, E.; Enyedy, É. A.; Csóka, H. A Comparison Between the Chelating Properties of Some Dihydroxamic Acids, Desferrioxamine B, and Acetohydroxamic Acid. Polyhedron 1999, 18, 2391-2398.
93. Farkas, E.; Enyedy, É. A.; Zékány, L.; Deák, G. Interaction Between Iron(II) and Hydroxamic Acids: Oxidation of Iron(II) to Iron(III) by Desferrioxamine B Under Anaerobic Conditions, J. Inorg. Biochem. 2001, 83, 107-114.
94. Sigel, H.; McCormick, D. B. On the Discriminating Behavior of Metal Ions and Ligands with Regard to Their Biological Significance. Acc. Chem. Res. 1970, 3, 201-208.
95. Lippard, S. J.; Berg, J. M. Principles of Bioinorganic Chemistry; University Science Books: Mill Valley, 1994.
96. Migdalof, B. H.; Antonaccio, M. J.; McKinstry, D. N.; Singhvi, S. M.; Lan, S.-J.; Egli, P.; Kripalani, K. J. Captopril: Pharmacology, Metabolism, and Disposition. Drug Metab. Rev. 1984 15, 841-869.
97. Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering High-Affinity Ligands for Proteins: SAR by NMR. Science 1996, 274, 1531-1534.
98. Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. NMR-Based Screening in Drug Discovery. Q. Rev. Biophys. 1999, 32, 211-240.
99. Ruf, M.; Weis, K.; Brasack, I.; Vahrenkamp, H. Modeling Transition State Analogues and Enzyme-inhibitor Complexes of Zinc-containing Class II Aldolases and Metalloproteases. Inorg. Chim. Acta 1996, 250, 271-281.
100. Spurlino, J. C.; Smallwood, A. M.; Carlton, D. D.; Banks, T. M.; Vavra, K. J.; Johnson, J. S.; Cook, E. R.; Falvo, J.; Wahl, R. C.; Pulvino, T. A.; Wendoloski, J. J.; Smith, D. L. 1.56 Å Structure of Mature Truncated Human Fibroblast Collagenase. Proteins 1994, 19, 98-109.
101. Puerta, D. T.; Cohen, S. M. Examination of Novel Zinc-Binding Groups for Use in Matrix Metalloproteinase Inhibitors. Inorg. Chem. 2003, 42, 3424-3430.
102. Abu-Dari, K.; Karpishin, T. B.; Raymond, K. N. Lead Sequestering Agents. 2. Synthesis of Mono- and Bis(hydroxypyridinethione) Ligands and Their Lead Complexes. Structure of Bis(6-(diethylcarbamoyl)-1-hydroxy-2(1H -pyridine-2-thionato-O,S lead(II). Inorg. Chem. 1993, 32, 3052-3055.
103. Barnett, B. L.; Kretschmar, H. C.; Hartman, F. A. Structural Characterization of Bis(N-Oxopyridine-2-Thionato)Zinc(II). Inorg. Chem. 1977, 16, 1834-1838.
104. Cohen, S. M.; Xu, J.; Radkov, E.; Raymond, K. N.; Botta, M.; Barge, A.; Aime, S. Syntheses and Relaxation Properties of Mixed Gadolinium Hydroxypyridinonate MRI Contrast Agents. Inorg. Chem. 2000, 39, 5747-5756.
105. Scarrow, R. C.; Riley, P. E.; Abu-Dari, K.; White, D. L.; Raymond, K. N. Ferric Ion Sequestering Agents. 13. Synthesis, Structures, and Thermodynamics of Complexation of Cobalt(III) and Iron(III) Tris Complexes of Several Chelating Hydroxypyridinones. Inorg. Chem. 1985, 24, 954-967.
106. Thompson, K. H.; McNeill, J. H.; Orvig, C. Vandium Compounds as Insulin Mimics. Chem. Rev. 1999, 99, 2561-2571.